Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Jul;17(19):2499-2512.
doi: 10.2217/fon-2020-1225. Epub 2021 Mar 26.

Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma

Roman Hájek  1 , Jiří Minařík  2 , Jan Straub  3 , Luděk Pour  4 , Alexandra Jungova  5 , Jesus G Berdeja  6 , Mario Boccadoro  7 , Lucie Brozova  8 , Andrew Spencer  9 , Frits van Rhee  10 , Jorge Vela-Ojeda  11 , Michael A Thompson  12 , Rafat Abonour  13 , Ajai Chari  14 , Gordon Cook  15 , Caitlin L Costello  16 , Faith E Davies  17 , Vania Tm Hungria  18 , Hans C Lee  19 , Xavier Leleu  20 , Noemi Puig  21 , Robert M Rifkin  22 , Evangelos Terpos  23 , Saad Z Usmani  24 , Katja C Weisel  25 , Jeffrey A Zonder  26 , Magda Bařinová  8 , Matyáš Kuhn  8 , Jiří Šilar  8 , Lenka Čápková  8 , Kenny Galvez  27 , Jin Lu  28 , Jennifer Elliott  29 , Dawn Marie Stull  29 , Kaili Ren  29 , Vladimír Maisnar  30
Affiliations
Free article
Observational Study

Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma

Roman Hájek et al. Future Oncol. 2021 Jul.
Free article

Abstract

Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov).

Keywords: effectiveness; ixazomib; multiple myeloma; proteasome inhibitor; relapsed/refractory; routine clinical practice.

Plain language summary

Lay abstract Proteasome inhibitors are drugs used in multiple myeloma (MM), a blood cancer that develops from cells in the bone marrow. Ixazomib is the first oral proteasome inhibitor to be approved for use in MM, when given in combination with two other oral drugs, lenalidomide and dexamethasone, to adult patients who have received one prior therapy. Our study, which was conducted in routine clinical practice, found that the effectiveness and safety of ixazomib + lenalidomide + dexamethasone in previously treated MM patients were similar to those seen in the Phase III clinical trial on which approval was based. These findings are important because they suggest that MM patients in everyday practice can achieve the same benefits from this treatment as patients in clinical trials, despite often being in poorer health.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

Associated data